infecti
diseas
remain
second
lead
caus
death
worldwid
cardiovascular
diseas
lead
caus
death
infant
children
vaccin
effici
tool
prevent
varieti
infecti
diseas
ultim
goal
vaccin
gener
pathogenspecif
immun
respons
provid
longlast
protect
infect
despit
signific
success
vaccin
develop
safe
strong
vaccin
still
requir
due
emerg
new
pathogen
reemerg
old
pathogen
suboptim
protect
confer
exist
vaccin
recent
import
emerg
reemerg
diseas
sever
acut
respiratori
syndrom
sar
influenza
pandem
ebola
viru
last
year
widespread
epidem
ebola
viru
caus
signific
mortal
sever
west
african
countri
result
awar
pursu
new
approach
toward
rapid
develop
vaccin
emerg
diseas
three
differ
type
vaccin
current
use
human
liveattenu
vaccin
inactiv
vaccin
subunit
vaccin
mani
effect
vaccin
use
liveattenu
vaccin
attenu
vaccin
compos
viru
bacterium
replic
within
host
type
vaccin
elicit
robust
humor
cellmedi
immun
cmi
exampl
liveattenu
vaccin
includ
mmr
measl
mump
rubella
chicken
pox
oral
polio
sabin
influenza
season
flu
nasal
spray
nasal
spray
rotaviru
yellow
fever
vaccin
inactiv
kill
vaccin
eg
inactiv
polio
salk
hepat
either
heatinactiv
chemic
inactiv
particl
pathogen
although
vaccin
safe
noninfecti
stimul
weak
shortliv
often
insuffici
immun
thu
larg
multipl
dose
inactiv
vaccin
requir
confer
protect
immun
contrast
liveattenu
vaccin
inactiv
vaccin
elicit
mainli
humor
immun
littl
induct
cmi
purifi
recombin
subunit
vaccin
deriv
nonliv
vaccin
antigen
poorli
immunogen
requir
addit
compon
help
stimul
protect
immun
case
vaccin
util
epitop
recogn
bound
antibodi
tcell
subunit
vaccin
contain
essenti
part
antigen
instead
entir
microb
chanc
advers
reaction
vaccin
rel
low
subunit
vaccin
made
hepat
b
viru
hbv
influenza
viru
inject
pertussi
part
dtap
combin
immun
recent
develop
subunit
vaccin
less
immunogen
reactogen
tradit
vaccin
liveattenu
inactiv
vaccin
thu
repeat
boost
immun
addit
adjuv
necessari
enhanc
efficaci
subunit
vaccin
word
adjuv
deriv
latin
adjuvar
mean
help
aid
adjuv
defin
agent
ad
vaccin
formul
enhanc
immunogen
antigen
induc
protect
infect
vaccin
made
liveattenu
inactiv
pathogen
elicit
robust
protect
immun
respons
vaccin
contain
natur
occur
adjuv
contrast
proteinbas
vaccin
case
limit
immunogen
although
advantag
term
safeti
costeffect
thu
adjuv
necessari
help
protein
becom
effect
vaccin
induc
strong
longlast
protect
immun
respons
inde
proteinbas
vaccin
success
develop
use
human
vaccin
mix
aluminium
salt
alum
howev
new
vaccin
target
requir
strong
antibodi
respons
also
robust
cmi
includ
helper
th
cell
cytotox
lymphocyt
ctl
alum
alon
insuffici
case
poor
induc
cell
respons
use
appropri
adjuv
allow
vaccin
formul
select
trigger
innat
immun
andor
adapt
immun
obtain
desir
type
antigenspecif
immun
respons
also
describ
practic
function
reason
adjuv
need
compon
vaccin
tabl
glenni
et
al
report
adjuv
activ
aluminium
compound
util
suspens
alumprecipit
diphtheria
toxoid
dt
aluminium
salt
wide
use
adjuv
human
vaccin
adjuv
use
practic
vaccin
year
gener
consid
stimul
immun
aluminium
salt
refer
alum
adjuv
one
contain
vaccin
licens
human
use
unit
state
alum
compon
licens
human
vaccin
hepat
viru
hav
hepat
b
viru
hbv
human
papilloma
viru
hpv
diphtheria
tetanu
haemophilu
influenza
type
b
hib
meningococc
although
number
adjuv
potent
alum
use
human
vaccin
formul
due
high
level
toxic
surprisingli
despit
wide
use
alum
adjuv
licens
human
vaccin
mechan
action
well
character
wellknown
mechan
action
alum
depot
effect
first
propos
glenni
wherebi
depot
format
cite
facilit
continu
antigen
releas
inject
site
even
though
depot
format
still
remain
somewhat
controversi
recent
studi
clearli
demonstr
depot
format
requir
alum
adjuvant
alum
shown
facilit
humor
immun
via
type
immun
respons
ige
eosinophil
advantag
alum
high
safeti
record
antigen
stabil
augment
high
longlast
antibodi
titer
howev
alum
abil
elicit
type
immun
cytotox
cell
respons
vaccin
contain
alum
adjuv
steril
filtrat
frozen
lyophil
emuls
unstabl
twophas
system
consist
least
two
immisc
liquid
combin
surfact
stabil
major
benefit
use
emuls
antigen
dose
spare
enhanc
antibodi
titer
novarti
glaxosmithklin
squalen
base
oilinwat
emuls
approv
pandem
influenza
vaccin
fluad
also
influenza
vaccin
focetria
celtura
europ
recruit
monocyt
macrophag
inject
site
induct
local
chemokin
secret
also
augment
antigen
uptak
dendrit
cell
dc
activ
cell
result
gener
high
antibodi
titer
balanc
respons
evalu
conjunct
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
hbv
cytomegaloviru
cmv
vaccin
trial
includ
licens
pandem
influenza
vaccin
although
contain
squalen
oil
differ
composit
contain
moral
et
al
demonstr
induc
nonspecif
activ
immun
system
mice
presenc
unfortun
recent
studi
report
possibl
associ
narcolepsi
use
adjuv
influenza
vaccin
although
oilinwat
emuls
seem
effect
promis
adjuv
detail
character
analysi
compon
use
emuls
prepar
need
examin
virosom
reconstitut
viral
envelop
possess
membran
lipid
viral
glycoprotein
devoid
viral
genet
inform
virosom
vaccin
influenza
viru
inflex
v
approv
europ
hepat
viru
epax
vaccin
approv
asia
europ
south
america
vaccin
util
virosom
deriv
influenza
viru
repres
immunopotenti
reconstitut
influenza
virosom
iriv
harbor
influenza
hemagglutinin
ha
protein
inflex
v
virosom
adjuv
influenza
vaccin
licens
age
group
includ
children
adult
elderli
virosom
adjuv
present
antigen
via
major
histocomp
complex
mhc
mhc
ii
virosom
abl
induc
humor
immun
cmi
major
advantag
use
virosom
vaccin
high
qualiti
longlast
antibodi
respons
conform
stabil
antigen
protect
antigen
degrad
excel
safeti
profil
suitabl
specif
popul
infant
immunocompromis
patient
elderli
tolllik
receptor
tlr
transmembran
signal
protein
compris
famili
pattern
recognit
receptor
prr
tlr
agonist
natur
ligand
activ
tlr
immunostimulatori
adjuv
advanc
design
effici
adjuv
base
use
tlr
agonist
promis
adjuv
alreadi
licens
human
vaccin
mpl
agonist
chemic
detoxifi
deriv
parent
lipopolysaccharid
lp
salmonella
minnesota
strain
mpl
increas
product
proinflammatori
cytokin
result
gener
immun
respons
compos
mpl
adsorb
aluminium
salt
two
vaccin
licens
human
use
hpv
vaccin
cervarix
hbv
vaccin
fendrix
haemodialis
patient
sinc
mpl
still
retain
abil
activ
innat
immun
interact
lead
activ
signal
product
proinflammatori
cytokin
chemokin
subsequ
chemokin
recruit
monocyt
macrophag
activ
dendrit
cell
dc
inject
site
matur
dc
migrat
drain
lymph
node
interact
tcell
stimul
cmi
benefit
use
adjuv
human
vaccin
effect
induct
robust
immun
respons
promot
product
achiev
use
alum
alon
recent
studi
show
antigen
coloc
lymph
node
order
elicit
adjuv
effect
antigen
present
cell
tlr
provid
bridg
innat
adapt
immun
new
class
effect
vaccin
adjuv
base
tlr
pathway
focu
tlr
clinic
trial
vaccin
infecti
pathogen
tlr
one
advanc
adjuv
candid
among
tlr
agonist
unmethyl
cpg
oligodeoxynucleotid
odn
type
tlr
agonist
enhanc
antigenspecif
immun
respons
induc
proinflammatori
cytokin
cpg
odn
exampl
immunostimmulatori
sequenc
iss
current
evalu
hbv
vaccin
heplisavb
dynavax
polyriboinosin
acidpolyribocytidyl
acid
poli
c
mimic
viral
dsrna
promis
candid
vaccin
adjuv
intracellular
pathogen
poli
c
bind
enhanc
robust
cmi
potent
type
interferon
respons
howev
major
drawback
stabil
toxic
issu
need
address
proceed
clinic
applic
dsrna
recent
clinic
safe
dsrna
polyi
c
analogu
ampligen
investig
adjuv
intranas
influenza
viru
vaccin
bacteri
flagellin
tlr
agonist
known
immunostimul
induc
high
antibodi
titer
mix
type
immun
respons
portion
flagellin
bind
tlr
express
fusion
protein
select
vaccin
antigen
due
characterist
flagellin
major
advantag
adjuv
fusion
protein
codeliv
antigen
agonist
apc
thu
flagellin
fusion
protein
suitabl
adjuv
develop
vaccin
induc
robust
antigenspecif
immun
respons
inde
flagellin
hemagglutininbas
vaccin
flagellinmatrix
protein
ectodomain
vaccin
clinic
trial
vaccin
influenza
although
studi
human
requir
appear
tlr
agonist
may
attract
candid
use
human
vaccin
iscom
anoth
promis
lipidbas
adjuv
format
iscom
spheric
ringlik
structur
spontan
form
upon
mix
antigen
saponin
cholesterol
phospholipid
compound
potent
immunostimulatori
saponin
extens
studi
adjuv
variou
vaccin
though
yet
approv
human
vaccin
use
due
toxic
sinc
iscom
allow
reduct
dose
consid
new
approach
overcom
issu
toxic
second
type
iscom
call
iscommatrix
nt
contain
antigen
major
advantag
iscom
iscommatrix
except
stabil
owe
high
affin
saponin
cholesterol
therefor
allow
effect
adjuv
mucos
vaccin
main
benefit
adjuv
induct
high
longlast
antibodi
titer
induct
balanc
type
immun
induct
cmi
includ
cytotox
cell
respons
adjuv
properti
iscom
iscommatrix
current
evalu
clinic
trial
influenza
hcv
hpv
collect
usag
iscom
iscommatrix
adjuv
could
altern
approach
vaccin
develop
infecti
pathogen
adjuv
system
gsk
refer
variou
combin
classic
adjuv
aluminium
salt
ow
emuls
liposom
immunostimul
design
adjust
adapt
immun
respons
pathogen
challeng
strategi
defin
best
combin
effect
safe
formul
individu
compon
synerg
one
anoth
elicit
robust
immun
respons
describ
tabl
ii
approv
adjuv
sever
human
vaccin
discuss
recent
develop
ident
addit
mpl
induc
bias
type
immun
respons
induc
high
antibodi
titer
domin
type
immun
respons
owe
addit
mpl
although
local
system
reactogen
report
clinic
trial
variou
vaccin
applic
includ
malaria
hbv
hpv
tuberculosi
hiv
combin
three
compon
liposom
mpl
unlik
design
improv
cell
respons
induc
robust
type
immun
respons
enhanc
antigen
present
apc
induc
high
antibodi
titer
recent
studi
demonstr
malaria
vaccin
induc
increas
igg
titer
polyfunct
cell
express
sever
clinic
trial
progress
vaccin
candid
infecti
pathogen
includ
hiv
tuberculosi
malaria
ultim
goal
vaccin
gener
potent
longterm
protect
diseas
protect
immun
elicit
use
vaccin
formul
contain
appropri
antigen
adjuv
adjuv
import
compon
vaccin
affect
outcom
vaccin
past
approach
vaccin
formul
adjuv
focus
singletyp
adjuv
alum
emuls
howev
new
vaccin
target
requir
induct
welldefin
cmi
addit
high
titer
antibodi
consequ
new
immunostimul
adjuv
vaccin
formul
need
order
stimul
robust
immun
respons
includ
humor
immun
cmi
great
progress
made
field
adjuv
research
last
two
decad
vaccinologist
abl
select
appropri
adjuv
classic
adjuv
immunostimul
combin
thereof
enhanc
vaccin
efficaci
taken
togeth
recent
success
clinic
studi
conduct
new
adjuv
suggest
panel
novel
immunostimul
adjuv
util
human
vaccin
formul
near
futur
avail
adjuv
variou
combin
facilit
ration
design
vaccin
infecti
diseas
